In short
Fast Money Podcast Notes Podcast Title: CNBC's "Fast Money" Episode Title: Markets Digest Latest Inflation Read… And Trade Desk Turmoil Deepens 8/14/25 Host: Melissa Lee Guests: Tim Seymour, Steve Grasso, Karen Feinerman, Guy Adami
---
Episode Summary In this episode, the Fast Money team analyzes the impact of recent inflation data, the fluctuating stock of Intel following potential government investment, and the struggles of Trade Desk as it faces client changes. The episode also covers the latest moves from major companies like Eli Lilly and the market's reaction to earnings reports.
---
Key Topics Discussed
- Intel's Stock Surge
- Key Event: Shares of Intel increased significantly on news of potential government investment.
- Market Reaction:
- Analysts discussed the implications of a U.S. stake in Intel and the broader semiconductor industry.
- Concerns were raised about the precedent this sets for government involvement in private companies.
- Statements from Guests:
- Tim highlighted Intel's historical significance and its alignment with national security interests.
- Karen noted the unusual nature of a government investment outside of a crisis context.
- Trade Desk's Decline
- Context: Reports of Walmart's advertising strategy changes led to a drop in Trade Desk's stock.
- Market Analysis:
- Jason Helfstein from Oppenheimer provided insights on Trade Desk's competitive landscape and its response to recent challenges.
- The discussion included the potential impact of Amazon's entry into the advertising space.
- Guest Opinions:
- The team debated the valuation of Trade Desk and whether it presents a buying opportunity.
- Eli Lilly's Price Increase
- Event: Eli Lilly announced a significant price hike for its diabetes drug, Manjaro, in the U.K.
- Implications:
- Dr. Kavita Patel discussed how this move might be part of a broader trend among pharmaceutical companies in response to pressure from the U.S. government.
- The conversation explored how pricing strategies might be tied to negotiations with Medicare.
- Inflation Data and Market Reaction
- Key Figures:
- The Producer Price Index (PPI) rose by 0.9%, indicating higher inflation than expected.
- Market Interpretation:
- Steve Leisman analyzed how this data might influence Federal Reserve policy, particularly regarding interest rates.
- Guests debated whether the latest inflation figures would lead to immediate changes in Fed strategy or if the current economic conditions warrant caution.
- Earnings Updates
- Tapestry: The stock dropped nearly 16% after cutting its full-year forecast.
- Deere: The equipment maker trimmed its outlook amidst weaker sales and profit figures.
---
Key Takeaways
- Intel's Surge: Reflects investor sentiment towards government support of tech companies, highlighting the intersection of national security and market dynamics.
- Trade Desk's Challenges: Emphasizes the volatility in the ad tech space and the impact of key client relationships on stock performance.
- Eli Lilly's Strategy: Indicates a potential shift in pharmaceutical pricing strategies that may affect consumer access and government negotiations.
- Inflation's Impact: Shows the complexity of economic indicators on market predictions and Federal Reserve decisions.
- Earnings Reaction: Signals how market expectations can rapidly shift based on corporate guidance and macroeconomic conditions.
---
Conclusion This episode of "Fast Money" delves into significant market developments driven by inflation data, corporate earnings, and strategic company moves, providing insights for investors navigating the current economic landscape.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:01Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money. Here's what's on tap tonight. National Intel shares the chipmaker popping on a report that the U.S. is considering taking a stake in the stock. The precedent that would set and what it means for the chip sector. And Trade Desk tumbles. The ad tech stock dropping on reports a major client is pulling back from the company. What will it take for shares to recover from here? Plus, Eli Lilly makes the moves on Manjaro. Corwee crumbles again ahead of lockup expiration. And Baba bobbles. Some major funds are selling the stock should you follow suit.
0:33I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Steve Grasso, Karen Feinerman, and Guy Adami. We'll get into this morning's inflation data in just a moment. But first, shares of Intel spiking late in the day on reports the Trump administration discussing taking a stake in the company. That after Intel CEO Lip Boutin visited President Trump at the White House just on Monday. Eamon Javers has the very latest developments. Eamon. Hey there, Melissa. What we've got now are a whole lot of no comments from all parties, Starting with the White House, take a look at this statement they put out just a short time ago.
1:07The White House saying discussion about hypothetical deals should be regarded as speculation unless officially announced by the administration. That is a no comment. What you don't see in there is a denial. Take a look at the Intel statement as well. Intel is deeply committed to supporting President Trump's efforts to strengthening U.S. technology and manufacturing leadership. We look forward to continuing to work with the Trump administration to advance these shared priorities. But we are not going to comment on rumors or speculation. There's that word again, speculation. What you don't see in either statement is a denial that this is being discussed behind the scenes, which is what the Bloomberg report said, citing people familiar with the situation.
1:49The Bloomberg report, a little bit thin on details. They don't have a price that the U.S. government is going to pay for this stake. They don't have a percentage of a stake that the U.S. government might take in Intel. Nonetheless, you see what it's done to Intel shares there late in the day here, Melissa. Back over to you. All right, Eamon, thank you. Eamon Javers, already going to the start. The stock was up a lot. It's up 19 percent on the week. Maybe the best thing that's happened to Intel in recent history is that President Trump picked on Lip Boutin. I mean, because that's what it looks like in terms of the stock performance.
2:20And I think we had that. We've been having the conversation. It hasn't panned out. Now it's starting to. And everything about Intel could be sort of the Taiwan, semi of Taiwan. Well, Intel could be sort of the same thing here in terms of the foundry business. It makes actually a lot of sense in terms of security being domiciled in the United States, dominating here. And we've said that for a while. Now it's starting to manifest in the stock. And I don't think this is over by any stretch. I mean, this had always been a pillar for a long time. And Tim, we've been talking about this for months, maybe longer, about how it is a national semiconductor company.
2:57And now under the Trump administration, if he wants to bring back manufacturing here, this makes 100 percent sense. But it makes sense or it would have made more sense in the context of let's provide incentives, let's provide opportunities for access to either government funds or loans or grants. It's not taking a stake. And so as the guy that's been investing in emerging markets a lot of his career, when you hear a government nationalizing a company, stocks don't rally 8 percent. They usually sell off dramatically. So I'm not saying that this isn't necessarily good news. And I think it's interesting that the White House was effectively talking down intel while maybe thinking about buying them.
3:38I think you've got a fascinating story because the Trump administration and a very different world order is very focused on national champion companies. And this is something that, again, I feel like I've been used to dealing with around the world. And that's fine. In fact, it may be the right move. Lip Boutin, who was known as Mr. Chip in China. I mean, the concerns that are coming out of, say, Ohio, I think are probably more. Ohio's a battleground state. It doesn't surprise me that making Intel and their lack of spending on more jobs in Ohio a potential target, and there's a whole political process that's going here.
4:18But there's no question that LiPoTan has a lot of relationships in China. This is a U.S. versus China chip war and tech war. And I do think that it's not only not surprising, but it's appropriate that people should make sure that Intel is properly a U.S. company focused on U.S. concerns. And, you know, if it's more of a public, excuse me, yeah, if it's more of a government-owned entity than a pure private entity, there will be that much more control. And maybe this is the day and age where we need to. But this is not conventional. And this is very surprising. It is not conventional, particularly post-Great Financial Crisis.
4:57as we were discussing during the great financial crisis, the government took stakes effectively in a lot of companies, including GM and the financials, Karen. But that was during a time of crisis. And for this to happen outside of crisis is unusual. I mean, maybe they think of it as a crisis, right? For Intel? For Intel. Clearly, Intel has, you know, the promise of Intel over the last few years hasn't borne out, right? So, but you're talking about to save the banking system, right? Right. They said every every major, you know, G-SIB had to had to issue it preferred to the government, whether they wanted to or not.
5:33And this is a very different situation than that. Although, you know, I don't know what kind of bargaining power Intel has. I don't know if they want this. Maybe they'll think it's great. I don't know. But I don't think they have a ton of bargaining power. So it's interesting. It is it's it's not. I wonder if we're going to see any more kinds of transactions like we haven't even seen one yet. It's a story of it. Well, I think this is more strategic. This is not a state-owned enterprise. This is a stake. And MP, they did take a 15 % stake in MP materials. So he sees this as strategic. Rare Earth, strategic.
6:10Chips, strategic. So if you come up with a bunch of different companies, he'll probably take a bunch of different other stakes. I don't really have a problem with it. I own Intel. So, of course, I want to see the stock go up. And you owned MP. And I owned MP. So for me, you know, I invested around those strategic companies. As long as they're just stakes and not state-owned enterprise, I think I'm okay with it. Right. And, Tim, going back to the emerging markets metaphor, I get that. But there is a board. Theoretically, the board will vote in some way on this. And isn't investing along with the government?
6:44I mean, you've got a government put, maybe the strongest put out there, in theory. As we've said with Alibaba, if I know the government's on my side now, then I'm a much more confident investor and maybe I've removed a lot of governance dynamics. But think of any country can dub any sector strategic. And that's what's happened. And I've invested in countries where they've dubbed 18 sectors to be strategic, which means suddenly they are no longer in the hands of the private sector. Now, again, decide what you want as an investor. this may be the right time in a world where globalization is dead to be betting more so on board with your government.
7:22And in this case, it's the U.S. government. And if there's a government in the world I'm going to bet with, it's the U.S. government. But I think we just need to point out what it is. And the dynamic here is one where calling something strategic, you can call anything strategic. And that's, in fact, what governments anywhere have the ability to do to give themselves the access into sectors if they want it. And so, look, we all recognize that, and I've said this before, that data is the new oil. So natural resources where everyone in the world in the past had to fight and call strategic interests were first.
7:57We weren't letting the Chinese buy our oil companies. We're not going to let them buy our chip companies. So this is just the world we live in. But but it is a different time. And this is along with MP. It is important to bring that up because the deals are very similar. Yeah. First MP, then then what? Copper, steel, you know, you name any other resource out there, nuclear power, you know, first Intel and then what? Is there NVIDIA? Is there you know, there's a lot of other sort of roads you can go down if you want to. Yeah. Well, yes. And, you know, what I find really fascinating, two weeks ago, and I'm a little hyperbolic, but Lipután was a Chinese operative, effectively.
8:42Right. Selling technology to China, to a Chinese military academy. And now, you know, so it's amazing how quickly things change in today's world. All right. Well, we'll just remember the talk of this U.S. Sovereign Wealth Fund. Right. Right. Where I don't know where the money was exactly coming from, But maybe they're just sort of piecemailing the U.S. sovereign fund together. True. And maybe there's another way of looking at it, too. Maybe Intel is in more trouble than they are projecting. And the U.S. government had to step in to help it along to make sure that it is not going to. The big question is, does this solve the problems to that very point?
9:20Does this solve the problems that the government, that Intel has had? Does this make them go from 15 percent market share above that? They're equal to Broadcom and NVIDIA owns market share. Tim, you want to get in? Well, just really quickly, let's not forget that Ohio is probably the most important state to win in our country right now. And Trump has won it and Republicans have won essentially the last three go rounds here. But if you think about where a lot of the uproar was coming on Intel, when the point guys referencing, you know, Bernie Moreno is someone that's been very supportive of President Trump.
9:56He's someone that's very politically savvy and somebody that is making a big deal out of what Intel hasn't done to fulfill commitments in Ohio, especially when Intel says we might not be done with this till 2030. This is very much about Ohio. This is very much about politics. And it just is what it is. Let's stick with the semi space here. An earnings alert on applied material shares dropping despite a beat on the top and the bottom lines. CNBC's Christina Parsnevelis is here with the details. Christina. Much of this has to do with the outlook and just the drop in demand coming from China. So they announced on the call that it's still ongoing that the China revenues or China contributed about roughly 35 percent to total revenues.
10:35That's going to drop to 29 percent. The CEO listed out three main facts as to why their outlook was less than what the street was anticipating. There was the weakness from China. They said that Chinese fabs were really ramping up spending in 23, 2024, not doing so much now. The second factor, which was interesting, is that the export licenses, they have still not got those through the U.S. government. And they said, quote, that they assumed none of these licenses will be issued in the next quarter. So that's a big sign for a lot of other chip makers that are going through the same problem, waiting for the U.S.
11:06government. Think of all the paperwork. I know NVIDIA is maybe getting a green light, maybe AMD, but that's about it. And the third point was they brought up nonlinear demand. So let's just call it lumpy demand from leading edge customers. Most notably, they don't call out TSMC, but the assumption is Taiwan Semi because Taiwan Semi was also mentioned in KLA's report. That is a peer to applied materials, seeing that there was a little bit of weakness. And then some rumors, even more so in the past few weeks, that TSMC is closing down some plants over there, more lagging edge. And so that would weigh on these equipment manufacturers.
11:37But applied materials does have more exposure to China. And the stock has really underperformed its peers, KLA and LAM Research, just a year to date thus far, and even chips overall. All right. Christina, thank you. Christina Parts Nevelis. Where'd you go with record quarter in revenue and the guide scares people. And now it's it's first of all, the stock has not traded well at all now for the last six months. Pull up a chart. Now we're getting towards levels that I think we got down to one twenty five or so in April bounced, obviously. But we're in the midpoint of that bounce. Valuation is never a concern here, but the guide is scaring people in this environment.
12:12If you guide lower, you're going to get punished. They should guide lower, though, right? I mean, there's a lot of big question marks here. So, I mean, maybe, you know, in the coming days people think, all right, well, that's a worst-case scenario. I don't know. It's not my thing. I wouldn't be near it. But if I were they, I would have put out just that same kind of release. Are we doing a would-you-rather? Because it felt like a little bit of a little bit. I was prepared for a would-you-rather, so I didn't know there would be homework. I don't even know what it would be. Versus KALAC? No, I mean, it depends on where you want to go in the semi.
12:44Yeah, it depends on where you want. No, it can't be versus, although I've been known to do that. I would go either Micron, where you're in danger of a little bit of a double top on the chart. But AMD is the natural competitor to NVIDIA. It's NVIDIA's world. Everyone else is just playing in it. I'd probably go with AMD, even though it's outperformed thus far. Yeah. Meantime, wholesale prices come in much hotter than expected in July, with the headline producer price index rising. Nine tenths of a percent from the prior month. It was the biggest increase since July of 2022. For more on what it could mean for the Fed, let's bring in senior economics reporter Steve Leisman.
13:21Does it change anything? Did it change any of the probabilities? It does, and it's kind of curious what happened after this hotter-than-expected wholesale price report. Mark, it's not so much rethinking September as rate cuts beyond September. I'll show you the data we're talking about. Up 0.9 on the headline. Fastest gain since the inflation of the pandemic. You take out food and energy and trade and services. The game was still a pretty robust 06. J.P. Morgan writing, the fact that there is upward pressure across all recent inflation reports that is not directly attributable to tariff goods may give some officials pause.
13:54St. Louis Fed President Alberto Musalem, he sounded like one of those officials with a little bit of pause inside of him, saying the Fed is still balancing potential weakness and jobs and an inflation level running at 3, while the Fed has a 2 % target. Despite the data, the futures market continues to price in a strong, a confident 93 % probability of a September rate cut. Now it's less sure about a second cut in October. That's kind of right around the toss of a coin level. And it's below the toss of a coin level for December. Both of those had been pretty fairly priced in. So that's where the action was.
14:25Tune in to Squawk Box tomorrow. We'll find out if Chicago Fed President Austin Goolsbee in the exclusive interview is on the pause or the cut side. The Fed and the market have got time for a meeting of the minds with the Fed expected. Fed speak expected next week from Jackson Hole. Another inflation and jobs report before the September meeting. So it's not a critical split right now, Melissa. But at least for now, it seems like the premise that perhaps inflation is OK right here and there's some weakness in the jobs report manifesting itself. But inflation may still come forward later on. According to those probabilities, that's what it seems like the market's pricing in at this point.
15:02I think that's right. If I could answer yes and put an asterisk next to it and tell you that the Jackson Hole conference is about the labor market. And we have hardly begun to speak about changes in the labor market relative to immigration and the labor force. Fed Chair Powell's talked a little bit about it. Mary Daly from San Francisco has. Goolsbee has as well. You have a big changes happening with the labor force right now because of what's happening with immigration. That factors in as well. So the Fed has this moving target on the inflation side with tariffs. It also has a moving target on the labor side.
15:35And the question is, what is normal in an environment where you have the labor force not growing as much? It could be that 75 ,000 or 50 ,000 is the normal run rate. The Fed may feel, hey, that's what we should be doing if labor force isn't growing. Steve, it's Karen. Thanks for being on. Does it matter really if they cut 25? I sort of think it sort of depends what Powell's, you know, is he dovish? Is he hawkish? What does a 25 really matter? I think that's right. I think the market is wondering how far and how long will the Fed remain above the neutral rate, which is somewhere in the 3%, 3.5 % range.
16:12You have Scott Besson, the Treasury Secretary, saying the Fed has 150 to give. And David Zervos, one of the candidates for Fed shares, saying the Fed should do 50 come September because it's behind the curve. of the Fed. I'm pretty sure it doesn't feel that way. And it's really interesting right now where the individual comments, Karen, I think have to be listened to pretty carefully because we had Jeff Schmidt from Kansas City talk tough in terms of his willingness to cut rates, saying he's sort of more of a hold guy. I thought Boussalam today was a little bit in the middle, but maybe leaning towards holding and we'll hear Goolsbee tomorrow.
16:44So it's a tough call right now. At the same time, have to give the news. Obviously, you know that Waller and Bowman, two Fed governors. They dissented in July. So Powell has his work cut out for him to try to balance these divergent views. They're in the market a bit, but they're also on the committee. All right. Steve, thanks. Good to see you. Steve Leisman. Tim, your take on PPI and markets?
17:11I think these numbers were not quite as devastating as the headline sounded or appeared, And if you strip out services, we're a big part of where the heat was. I know we're a services economy. But on the good side, if you strip out food and energy, we were at point three, which is where we've been. So but I think that given all the rhetoric, giving all the angst, given all the concerns about the Fed as an institution and where are we in going into the Powell change and the new Fed governor, this is a number that based upon the Fed we've had from this point going in reverse, they would not be going in September with this PPI.
17:47I'm sorry. So, again, I don't think this was a terrible number. But the Fed we've had so far, I don't think moves on this number. And that's what makes this number fascinating. The key is obviously, I think, straight down the barrel of labor and the employment number that we have the first week of September. That's going to make the call. Tim's right to break down the number, but it's still the hottest PPI, I think, since March of 2022. Corps back above three. And you have an administration calling for Treasury Secretary best on 150 basis points. The president 300. Doesn't really make a lot of sense, in my opinion, given those numbers.
18:23But I'll say this. If you had told me last night what these numbers are going to be, we play that game. S &P is down 80 handles, 90 handles. No, I'm being honest. Tenure yields above 4.35 and nothing really happened. This number is extremely volatile. Next month, it'll trade lower. It'll be lower than it comes in. But remember, two weeks ago, we thought we were in a recession because the jobs numbers were so awful. So these things change very quickly. I think he does cut in September, and I think he cuts one more time in December. It's not going to be 50 basis points, but it'll be 25. Coming up, Berkshire buying in while the Oracle of Omaha is taking a stake in beating down UnitedHealth.
19:06And the other updates from so-called smart money, that is next. and offloading in the China trade, big funds dumping mainland stocks. What it means for a few of our trader acronyms as BABA gets beaten down. Do not go anywhere. Fast Money is back in two.
19:28Welcome back to Fast Money. Shares of embattled UnitedHealth jumping after news Berkshire Hathaway has taken a stake in the insurer. CNBC's Leslie Picker has the details on that and some other buys by Berkshire. Leslie. Hey, Melissa. Yeah, it was an interesting quarter. Berkshire Hathaway taking a new stake in UnitedHealth, sending that beleaguered stock soaring in after hours, trading up 8 percent right now. Warren Buffett's firm held about$1.57 billion worth of UnitedHealth as of the end of Q2. Appaloosa also making a big bet on UnitedHealth, adding 2.3 million shares to hold$764 million worth, now the firm's largest single-stock position there.
20:08Michael Burry's Scion also bought a lot of notional exposure to UnitedHealth worth over$100 million as of the quarter end. Berkshire Hathaway also revealing three mystery stocks that had been omitted from the Q1 filing due to special confidential treatment. This quarter, we learned the firm took new stakes in steelmaker Nucor and homebuilder D.R. Horton and built a new class of shares in its peer, Lennar. Those three stocks also higher in after-hours trading, along with UnitedHealth. Nucor up about 6 percent, Lennar up 4 percent, and D.R. Horton up 3 percent. Just a reminder, though, all of these positions are as of the end of June and may have changed in the six weeks since.
20:47Melissa? Leslie, I also want to ask you about CoreWeave, which you've been following during the day, the lockup expiration. But you've also got some new reporting. The stock is down 3 percent after hours on top of the 15.5 percent decline in regular session. Yeah. So this is an interesting one, Melissa, because as we talked about earlier today, there was a lockup as of the end of the trading day today, as of the aftermarket. So the fact that we see shares down 3 percent, I have a couple of inbounds saying that the blocks are out there for sale. They're looking at prices above where it's trading now at about$97.
21:20So we'll see how many of those hold at that price range. Usually with these block deals, you see a discount because they're being done in a privately negotiated transaction. And if you do see a lot of these coming out at the same time, which is obviously the concern of the market, those shares down 15 % today, there's a concern that the discount will be there as well as the additional supply into the market. So usually people who are going to be onboarding those shares from a block will do so at a discount. So you can see those shares down 3 % right now. All right. Leslie, thank you. Leslie Picker.
21:55A lot to trade here. Where do you go? Well, CoreWeave, if you have a problem, which I do with NVIDIA having the bulk of their revenue coming from four different customers, CoreWeave's 77 % is coming from Microsoft and NVIDIA. I can't buy a stock like that. It leaves too much open-endedness for me. All right. UnitedHealth is a very interesting, it seems like the popular pick here in 13F land. I mean, I think actually the Appaloosa thing, well, it took a leg higher when the Berkshire F came out. And then it took another leg higher when the Appaloosa won. That was more of an aggressive bet. You think of Berkshire as much more long term.
22:32And I wouldn't be, this is, it's a billion, it's not chump change, but it is to Berkshire. So I find that interesting, though. It would probably be good for all that whole space. On July 28th, I sat here and said, because I think UNH reported on the 29th, I said, given what's happened, given where it is, if they say something incrementally positive, it's a$325 stock, which is still a blip, but a decent move, proceeded to say nothing good. And I think it traded down to like$238 or something like that. Now, here we are back at these levels. Again, they haven't said anything, obviously. Nothing has changed.
23:06But you see people like this getting behind them. I think the bet is they'll get through this difficult patch. We can wrap our head around a lot of different things that they do, and we're willing to sort of take some short-term pain. So it should trade back to 325 on this news. There's a lot more Fast Money to come. Here's what's coming up next. China's stocks get choked up. Shares of some of the country's biggest names dropping as major investors hit the sell button. Is there more downside of the names, or is this a time to buy? Plus, an advertising adjustment. Why shares of Trade Desk are getting hit yet again.
Read the full transcript
23:44And how to play the stock now. You're watching Fast Money, live from the Nasdaq market side in Times Square. We're back right after this.
23:58Welcome back to Fast Money. Some big funds bailing on China. Recent filings showing the Saudi sovereign wealth fund, PIF, cutting its stake in Alibaba to zero. Well, Bridgewater Associates sold all of its Chinese holdings, which included Baba, Baidu, Yum China and EV maker NIO. Tim Seymour, what do you think of those trades? I think it's a great time to add when big players are selling. And we've all just said that it's not necessarily a development that is in any way timely. But if I even just look at the stock chart, because, you know, the fundamentals on Baba, I'll let other people speak. I know there's some other bulls on the desk.
24:36I'm very bullish, very bullish on valuation. I'm very bullish on the comps being very easy. I'm very bullish on AliCloud. I'm very bullish on different parts of the business exposed to networking, excuse me, data center and some of that growth. But more importantly, in terms of the technical aspects of what those statements and those headlines look like, when Tiger Global's running out the door, they're another one. I mean, it just, to me, there was a fair amount of pressure on the stock in 2Q. I feel like the price action over the last six weeks has been very strong. And I think that chart reflects it.
25:06So this is a case where those negative headlines looking backward at 13 Fs is something that actually has me bullish. So a couple of things. One of the things that hit Alibaba today, I don't think the PIF thing, I agree with Tim. To me, that's a non-issue. The sort of competitive position of delivery, the delivery space over there is really coming under pressure. That's what hit JD.com. And so Alibaba is right in that space. So you've got to think there's some margin pressure there. To me, the most important holder in this area is Appaloosa, not PIF or Bridgewater. None of that matters as much.
25:46So to me, him selling some. Now, granted, it's been a huge bet. He was, remember, buying everything, which he reiterated a number of times, and it's been a big run. So to me, I saw that F. I sold some because I think Apple is such an important sort of, I don't know, sentiment indicator. Right. But importantly, you are still long. I am still long. And it is still the A in your car. You think I would ever change the A? Is it the A or the B? It's the A. It's the A. No, I would. Can we change? No, you can't change. No, I am still long. I had bought some more. I sold it. All right. Coming up, another trip up for Trade Desk.
26:21What Walmart has to do with that stock's most recent drop today? And the response from Trade Desk. The details when Fast Money returns.
26:39Welcome back to Fast Money. Stocks closing off their lows as investors digested this morning's hot inflation report. The Dow and Nasdaq both fractionally lower. The S &P eking out a third day of gains, but just barely. Shares of CoinDesk operator Bullish higher in its second day of trading. The crypto exchange up another 10 percent after its 83 percent surge in yesterday's debut. It is still lower than where it opened on Thursday. Major cryptos pulling back, though. Bitcoin, Ethereum both hit records in early trade, but ended the day lower. Solana also lower. Meanwhile, ad tech stock, the trade desk, tumbling again today on reports.
27:09It could lose another big chunk of its business. The information reporting that the company's deal with its largest client, Walmart, is no longer exclusive. The report adds that Amazon is making major inroads with some of the Trade Desk's other major clients, especially in the streaming space. The company just putting out a statement this hour, denying the rumors, saying the Trade Desk and Walmart Connect are fully committed to the partnership and continue to innovate together. For more on what's next for the company, let's bring in Oppenheimer Managing Director of Internet Equity Research, Jason Helfstein.
27:39He's got an outperform rating, a$70 price target on the name. Jason, great to have you with us. Thanks. And you did cut the price target, correct, on the back of that 30 percent drop on the back of earnings? We did. Our price target is 70 now, which would still be like 25, 26 times next year's cash flow. So still rich. But stock is 18 now. Apple 11, which kind of is the darling now, the sector is 26. And Roku is trading at about 21 times. So, you know, Meta is 15. So really, the question is, you sit here and you look at how much the stock's been hit and you say, could it go to 15? Yes. But it just feels like there's much more likelihood the stock will be back, you know, well over 20 after the next quarter.
28:26There seems to be, though, maybe it's a messaging problem. Let's say that you're right and the bullish thesis is still intact. In fact, you know, a lot of analysts walked away, a lot of investors walked away from that earnings call, believing that management basically dismissed Amazon as a competitor when Amazon does seem like it would be a competitor in this space. So what are your thoughts on that? Do you think that the company should worry about Amazon and isn't? Do you think that the company is more likely to partner with Amazon? Where does Amazon play into its market? Sure. I mean, the digital media space is quite enormous, right?
29:05I mean, look, technically, you know, you know, Meta, Google, these are all competitors, right? The real question is, is Amazon's DSP, right, which is one of their kind of, you know, three ad businesses, is that a direct competitor? I think they need to acknowledge a bit more the risk around certain categories like CPG. So they've said that auto and CPG is a third of their business. So let's just say half of that is CPG. So we're talking like maybe 15 % of their business, 15, 17%. That business is probably a risk because Amazon has great data on what CPG consumers buy. But Amazon does not have great data on auto.
29:48They don't have great data on financials. They don't have great data on telecom. They don't have great data on travel. So ultimately, I think there is some risk to Amazon, but I don't think the risk is significant. And I think there's just another point. It doesn't make sense to use multiple platforms. So Trade Desk is a demand side platform. You should use one, not multiple, or you give up efficiencies if you do that. Jason, I get the valuation is a problem in Trade Desk. I didn't think the quarter was a disaster. Maybe the guidance scared some people. But I'm going to ask you this. If they can sort of implement AI and sort of re-ratchet margins, new CFO, does this begin to look interesting again to you?
30:33I do, but I'm not sure, you know, how much of it is going to be, let's say, margin driven. I think this is really more sales focused, right? Like, it's just people focused on that five-point decel in the second quarter and then kind of got in for another two-point decel. And, again, to your point, there's been a number of management changes. It's not just CFO. The head of their sales left. I think they dismissed, call it, six weeks ago. They appointed a new COO at the end of last year, never had a COO before. So as we titled our note for the quarter, you know, not executing at peak levels, we think a good amount of this is self-inflicted.
31:18But really where, you know, they need to show more progress is with this new operating system. They call it Kokai. And Kokai is supposed to generate 20 percent better revenue for them, but also better performance from their advertisers. So you ask, like, why did this Amazon, why did this Walmart news come out? Right. Some of this is like a pylon. I'm sure Walmart would like to pay less. You know, is this, you know, is there some negotiating going on and kind of rates and fees behind the scenes potentially? But ultimately, I don't think anyone has a better mousetrap in the market right now for brand formants, which is really what it is.
31:59It's being able to measure brand advertising on the Internet. Jason, thanks for joining us. Appreciate it. Thank you. Jason Helstein of Oppenheimer. Tim, what do you mean? I mean, that's an interesting point in terms of maybe they're negotiating. The report specifically mentioned Walmart doesn't like the fees that Trade Desk charges. Yeah. Yeah. And what Trade Desk reported in that release, you know, just quoted something from Walmart back in June, too. So, I mean, I assume the world's the same, but you don't know. I think the space is wildly competitive and I think technology may be changing competitive advantages.
32:36I do think Trade Desk is the biggest and the most kind of uniquely positioned as being a player that is non-biased and is seemingly looking to do the best on behalf of the advertiser. But I think the valuation is tough and I think the uncertainty remains. I'm not sure this is one you grab on not just some weakness, a lot of weakness. When it sounds like a soap opera, you go to the charts. And the charts look like low to mid-40s is where the support is on this. It sounds like a big move, but when you look at the chart, it's extremely choppy. And those support levels go back about five years or so on a chart.
33:16So I would wait. And definitely, if you're going to buy on a dip, divide it up into a couple of 20 % lots instead of jumping all in. I can't speak to the chart part, but that's interesting. I sort of agree with Tim. I mean, it is not cheap. It's not like, wow, they have really discounted this thing. It's crazy here. But I understand they're in a unique, you know, it is a great business. But at this valuation, I think it hasn't priced in what I think is more headwinds to come. Coming up, price hikes across the pond while Eli Lilly is nearly tripling the cost of its weightless drug in the U.K. as pressure from the Trump administration weighs in the pharma space.
33:53Do not go anywhere. Fast Money is back in two.
34:04Welcome back to Fast Money. Eli Lilly, the best performing stock in the S &P today, up nearly 4%. The company announcing it is raising the list price of its blockbuster diabetes drug, Monjaro, in the UK. President Trump has been pressuring Big Pharma to get U.S. drug prices more in line with the rest of the world. Most favored nation status. Let's bring in Dr. Kavita Patel, who's an NBC News and MSNBC medical contributor. She served in the Office of Intergovernmental Affairs and Public Engagement under President Obama. Dr. Patel, great to see you. Thanks for having me. Is this just the first in terms of the effort by Big Pharma to raise that price around the world, to sort of narrow that gap between prices here and prices overseas?
34:47Yeah, Melissa, I think you're seeing this. This was part of an act kind of issued by the administration. in the form of a letter to 17 of the large manufacturers, with Eli Lilly being up front with an address letter to the CEO. So I think you can tell that Lilly doing this isn't shocking, and I think that we'll see more to come. I do think a lot of what's happening in the background is being able to leverage this tradeoff in price and this rebalancing in the UK and in the EU, or also being able to guarantee that they can be at the table to negotiate some sort of demonstration or some sort of program around Medicare.
35:19Remember, the United States is their big market. And having that share in both Medicare and Medicaid is everything for drugs like Manjaro. So this is important. And I don't think they'll be the only one that we see. Dr. Patel, it's Tim. Always great to have you. And I guess let's shift the focus back to the Orpho news and the sense that this might have been their their novo moment. What's the market's reaction here? Is it an overreaction? And again, it's really looking at long term kind of targets on revenues in the short term. Nothing really changes. I'm just trying to get your sense on was this an overreaction?
35:55Because there's even a sense that some of this GLP trade because traders are looking at stocks that have almost nothing. And now that Lilly's really kind of had their novo moment that this trade's over. Right. I do think that the Orpho news was like, even though that it wasn't quite what we had expected it to be, it was still seen, interestingly enough, by the clinical community as a win because it offers like an oral option. So I do think, you know, the way the stocks reacted on the release of that news, but now kind of combined and paired with at least Lilly signaling that they're going to do everything that they can to kind of keep the global market and to keep that in play.
36:32I do think that this is where I wouldn't have projected kind of the, you know, 4%. I wouldn't have kind of put it at that level of kind of opinion around how to expect that news out of the UK today, to be honest with you. So I think some of us are trying to understand, is this really just about this rebalancing or is it a little bit of catch up on, hey, now there's been some positivity after Orpho. There's some really like interesting momentum. There's this hype about the obesity AI deal. Could that be playing into part of it? Because AI is also having its moment in drug discovery as much as I think that might pop at some point.
37:08This is still kind of the game that they're playing. And Lilly is doing a great job of delivering on clinical results. And I think that's part of like what's catching up. But the markets, some markets are not necessarily responding on clinical data as I would have expected it to. So to me, this is a signal that they're sitting at the table negotiating some demonstration and doing something with Medicare, And that's going to be big. Yeah. Just to get back to the Orpho data, Dr. Patel, the full readout is going to be next month. And I'm wondering, as a clinician, what are you going to be looking at specifically in that readout that might, you know, confirm your view that this was not a disappointment?
37:49Because the investment community takes a look at the weight loss numbers and also takes a look at the discontinuing rates. And they are disappointed. They are. So I'm going to be looking at more details around kind of the discontinuation rate as well as kind of the side effects. Because remember, in the clinical realm, everything that we're seeing are discontinuations, largely because of either side effects and or costs. And so we haven't heard anything. We're not going to hear it next month either, Melissa, around costs around the oral drugs. So I don't expect that to come out. But I do think we're going to see much more detailed data around how the different.
38:21And we also did hear a little bit about some of the differences in the cohort on the dosing. And we saw that max dosing got you pretty darn close to the injectable. So I'll want to see the breakout by clinical groups. I'd want to see, remember, this is a group that did not have diabetes, but they had other comorbidities. I'd be very interested in seeing if there's a pattern with some of those other comorbidities and then the detailed side effect profiles. Because if we can even see, Melissa, an even incremental lower side effect profile, not the discontinuation rate, but even a slightly statistically significantly lower side effect profile with a drug like Manjaro that's already had a decent side effect profile, that just makes it an even more compelling argument.
38:58And then again, the last remaining variable that we won't get is cost. But I think everyone's anticipating that the cost because of supply chain issues and how we make these drugs will not be as high as the injectable, but that remains to be seen. Dr. Patel, great to see you. Thanks. Thank you. Dr. Kavita Patel. Coming up, harvests and handbags. The results weighing on shares of Deere and Tapestry. That's next. More Fast Money in 2.
39:31Welcome back to Fast Money. Some morning earnings movers catching our attention. Let's start off with Tapestry. That stock dropping nearly 16 percent, the worst performer in the S &P today, despite topping EPS and revenue expectations. The coach and Kate Spade Parent cutting its full year forecast, citing an expected$160 million tariff hit. Steve, I'll go to you on this one. Yeah, I'm not in it now. It seems like the Kate Spade is the problem, Coach is the luxury brand, and Kate Spade is the everyday brand and is more ubiquitous. But I think at this point, they spent so much money on that Capri takeover that didn't work out.
40:08They hemorrhaged a little bit of cash, and I think there's a reset moment for the stock now. So they have a good deal of specificity on what they thought the tariffs would be, which I found interesting. Right. Now, I know that they've probably diversified the way the supply chain have other. So it makes me think that number is really a very conservative number. And this was a good quarter. Nobody's disputing that. It was about the guidance. But that made me think, OK, it's a bad case scenario. Prior all time, I was about 90-ish. Then it sold off. and then it was a rocket ship from basically, I don't know, March on.
40:4590 should be support. Steve's right. I mean, it's a coach story, which is still a very strong story. I think you buy it at 90. All right, let's get to Deere now. That stock also lowered the heavy equipment maker, trimming the top end of its full-year outlook. As profits and sales fell in its fiscal third quarter, citing weaker volumes and a challenging environment, shares are down almost 7 % here. Tim, did you think they were just being conservative on guidance? I think they're often conservative, and so that's fine. But shouldn't they be right to be somewhat conservative about the environment they're in?
41:17And so today's PPI gives you kind of some sense also. I mean, there's significant inflation running through the system. It may not be passed on to the consumers yet, but it may be along the producer side where I think Deere really has more exposure. So what a great run, though, over the last, say, two to three years in Deere. And I think investors should be looking for an opportunity to add to weakness. Yeah. URI, I noticed was lower. Is that partially on this? I think so. Right. And just it had run so far so fast. 435, if you go back and look, was sort of this level. Couldn't get through for a couple of years.
41:52Tim's right. Since then, it's been off to the races. Prior resistance becomes support. 435 is your level. Up next, final trade.
42:09time for the final trade let's go around the horn tim i got a happy birthday to my little guy connor who just turned 12 the man united united health care 17 times that's cheap happy birthday connor steve i usually like to stay away from ipos and see how they settle out but i like the stock bullish parent yes happy birthday connor sat right in that chair did a good little final trade remember that But if we see a further sell-off in China, I would buy FXI. You know, you can tell the next two weeks it's going to be extraordinarily busy. I'm glad we're going to have your stewardship here to guide us through.
42:47I'll be on vacation. See you after Labor Day. You're going to tell us when. Do you have a final, right now, final, final trade? I think Netflix turns. All right. Thanks for watching Fast Money. Mad Money with Tim Kramer starts right now.
43:04All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:38To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
Yields spiking as markets digested this morning’s hot inflation data. How our traders are navigating the market’s reaction, and what the PPI report means for the Federal Reserve’s next rate move. Plus Trade Desk shares taking another big blow on reports that Walmart is changing up its advertising strategy. What it means for the company’s business, and what one analyst sees in store for the ad space.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
